- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Moving PSE to Rx-only in Mo. lacks fiscal sense
- Medication adherence could be blockbuster for specialty
- Walgreens launches high-impact push in support of World AIDS Day campaign
- Gallup: Take Care Clinics top in customer service
SCHAUMBURG, Ill. The Food and Drug Administration has approved a generic injected drug made by Sagent Pharmaceuticals for treating migraine attacks, Sagent said Monday.
The FDA approved Sagent’s sumatriptan succinate injection in the 6 mg per 0.5 milliliter strength. The drug is used to treat acute migraine attacks and cluster headache episodes.
Sumatriptan is a generic version of GlaxoSmithKline’s Imitrex. Injectable sumatriptan had $22 million in sales in 2009, according to IMS Health.